Arca
Skip to content
Tools
Tools

Atherosclerosis

Drug research and approvals for atherosclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 395 studies of atherosclerosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.

  • Recruiting worldwide: 395
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 395 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 7

Phase 3 12 of 47

Phase 2 12 of 13

Phase 1 or earlier 6

How its trials ended

1,497 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 284 whose ending is known, 40% met their primary endpoint, 18% missed it and 43% stopped early.

  • Completed, result not reported65744%
  • Ongoing29520%
  • Status unknown26117%
  • Met its primary endpoint1138%
  • Stopped: other or unclear674%
  • Missed its primary endpoint503%
  • Stopped: enrollment or feasibility252%
  • Stopped: sponsor or business decision121%
  • Stopped: funding121%
  • Stopped: lack of efficacy4<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 10, 2026A randomized, multicenter, double-blind, parallel, placebo-controlled phase 2b clinical trial to evaluate the efficacy and safety of YN001 in adults with…YN001 (liposomal rosuvastatin)Beijing Inno Medicine Co., Ltd.Pending
Nov 21, 2025A phase IIa, multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, pharmacodynamics, and pharmacokinetics of selnoflast in…Selnoflast (IZD-334, RO7486967)RocheOngoing
Jun 24, 2024Platelet therapies for intracranial vascular atherostenosis (CAPTIVA)Rivaroxaban / Ticagrelor / Clopidogrel / Asa (acetylsalicylic acid)University of FloridaClosed
May 14, 2024Nuance-icad: effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy in symptomatic intracranial atherosclerotic disease:…TicagrelorSunnybrook Research InstituteOngoing
Jun 7, 2022A randomized, double-blind, placebo-controlled, phase 2b study of isis 678354 in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease…Isis 678354Ionis PharmaceuticalsClosed
Sep 17, 2020Metabolic and metagenomic effects of repopulation of the intestinal microbiome in patients with severe unexplained atherosclerosis.Fecal microbiota transplantationSt Josephs HealthcarePending
Aug 28, 2017Mineralocorticoid receptor antagonism clinical evaluation in atherosclerosisSpironolactoneUniversity Hospitals Cleveland Medical CenterOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.